MetLife Investment Management
XENE icon

MetLife Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

MetLife Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45M Buy
57,221
+9,878
+21% +$548K 0.02% 849
2026
Q1 		$2.75M Buy
47,343
+5,318
+13% +$245K 0.01% 894
2025
Q4 		$1.88M Sell
42,025
-2,196
-5% -$92.2K 0.01% 1101
2025
Q3 		$1.78M Sell
44,221
-1,326
-3% -$46.7K 0.01% 1145
2025
Q2 		$1.43M Buy
+45,547
New +$1.49M 0.01% 1148

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MetLife Investment Management's XENE Position: Q2 2026 in Review

MetLife Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 21% in Q2 2026, buying an estimated $548K and bringing the position to 57,221 shares worth $3.45M. The position accounts for 0.02% of the portfolio, ranked #849.

MetLife Investment Management first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • MetLife Investment Management held 57,221 shares of Xenon Pharmaceuticals worth $3.45M as of Q2 2026.
  • MetLife Investment Management bought 9,878 Xenon Pharmaceuticals shares in Q2 2026, an estimated $548K.
  • Xenon Pharmaceuticals made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #849 holding.
  • MetLife Investment Management first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.